Pharmaceutical Freebies and Medical Ethics: Should India Enact a Binding Statutory Framework to Regulate Pharmaceutical Marketing?
DOI:
https://doi.org/10.5281/zenodo.23308824Schlagwörter:
Pharmaceutical marketing, Medical ethics, Uniform Code of Pharmaceutical Marketing Practices, Health Law, Medical LawAbstract
Indian doctors have been barred from accepting gifts, hospitality and cash from pharmaceutical companies since 2009, and companies are subject to a marketing code revised in March 2024. Yet no statute directly prohibits the inducement itself. This article asks whether India should enact a binding statutory framework to regulate pharmaceutical marketing. Using doctrinal and comparative analysis, supported by the medical-ethics and health-policy literature, it examines the professional regulations, the Uniform Code of Pharmaceutical Marketing Practices 2024, the Supreme Court’s decision in Apex Laboratories (2022) and the pending petition in which the Court, on 8 October 2026, directed the Union government to constitute a committee on the question. The article argues that the current arrangements leave five gaps: no statutory prohibition on inducements, weak sanctions, fragmented enforcement, no public register of payments and easy circumvention through indirect channels. It contends that a statute is constitutionally secure under Articles 21 and 19 and is workable in light of experience in the United States, France, the European Union and the United Kingdom. Its contribution is a design for a narrow, proportionate law built on prohibitions with defined exceptions, a searchable payments register, layered enforcement with credible sanctions and complementary reform of medical education funding.
Downloads
Literaturhinweise
Apex Laboratories Pvt Ltd v Deputy Commissioner of Income Tax (Large Taxpayer Unit-II), SLP (C) No 23207 of 2019 (Supreme Court of India, 22 February 2022).
Association of the British Pharmaceutical Industry (2024) ABPI Code of Practice for the Pharmaceutical Industry 2024. London: ABPI.
Ayres, I and Braithwaite, J (1992) Responsive Regulation: Transcending the Deregulation Debate. New York: Oxford University Press.
Beauchamp, T L and Childress, J F (2019) Principles of Biomedical Ethics. 8th edn. New York: Oxford University Press.
Brax, H et al. (2017) ‘Association between physicians’ interaction with pharmaceutical companies and their clinical practices: a systematic review and meta-analysis’. PLoS ONE 12(4): e0175493.
Central Board of Direct Taxes (2022) Circular No 12 of 2022: Guidelines under section 194R of the Income-tax Act, 1961 (16 June 2022).
Choudhury, R (2026) ‘Supreme Court orders formation of committee to examine issue of pharma companies giving freebies to doctors for prescribing their drugs’. Bar and Bench, 8 October 2026. Available at: https://www.moneylife.in/article/supreme-court-orders-formation-of-committee-to-examine-issue-of-pharma-companies-giving-freebies-to-doctors-for-prescribing-their-drugs/81889.html.
Consumer Education and Research Centre v Union of India (1995) 3 SCC 42.
Consumer Protection Act 2019 (India).
Dana, J and Loewenstein, G (2003) ‘A social science perspective on gifts to physicians from industry’. JAMA 290(2): 252–255.
DeJong, C et al. (2016) ‘Pharmaceutical industry-sponsored meals and physician prescribing patterns for Medicare beneficiaries’. JAMA Internal Medicine 176(8): 1114–1122.
Department of Pharmaceuticals (2024) Uniform Code for Pharmaceutical Marketing Practices 2024 (12 March 2024). New Delhi: Ministry of Chemicals and Fertilizers.
Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use.
Drugs and Cosmetics Act 1940 (India).
Drugs and Magic Remedies (Objectionable Advertisements) Act 1954 (India).
Drugs (Prices Control) Order 2013 (India).
Federation of Medical and Sales Representatives Association of India (FMRAI) v Union of India, Writ Petition (Civil) No 323 of 2021 (Supreme Court of India) (cited as FMRAI v Union of India 2022 for the March 2022 notice).
Fickweiler, F, Fickweiler, W and Urbach, E (2017) ‘Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians’ attitudes and prescribing habits: a systematic review’. BMJ Open 7: e016408.
Frankel, T (2011) Fiduciary Law. New York: Oxford University Press.
Fugh-Berman, A and Ahari, S (2007) ‘Following the script: how drug reps make friends and influence doctors’. PLoS Medicine 4(4): e150.
Gagnon, M-A and Lexchin, J (2008) ‘The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States’. PLoS Medicine 5(1): e1.
Human Medicines Regulations 2012, SI 2012/1916 (United Kingdom).
Income Tax Act 1961 (India).
Indian Medical Council Act 1956 (India).
Justice K S Puttaswamy (Retd) v Union of India (2017) 10 SCC 1.
LiveLaw (2022) ‘Supreme Court issues notice on plea to give statutory basis to the Uniform Code of Pharmaceutical Marketing Practices’, 11 March 2022. Available at: https://www.livelaw.in/amp/top-stories/supreme-court-uniform-code-of-pharmaceutical-marketing-practices-pharma-companies-193968.
Lo, B and Field, M J (eds) (2009) Conflict of Interest in Medical Research, Education, and Practice. Washington, DC: National Academies Press.
Loi no 93-121 of 27 January 1993 (France).
Loi no 2011-2012 of 29 December 2011 (France).
Medical Council of India (2002) Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002, as amended.
Modern Dental College and Research Centre v State of Madhya Pradesh (2016) 7 SCC 353.
National Medical Commission (2023) Registered Medical Practitioner (Professional Conduct) Regulations, 2023 (notified 2 August 2023; held in abeyance 23 August 2023).
National Medical Commission Act 2019 (India).
Paschim Banga Khet Mazdoor Samity v State of West Bengal (1996) 4 SCC 37.
Patient Protection and Affordable Care Act 2010, Pub L 111-148, s 6002 (United States); Anti-Kickback Statute, 42 USC § 1320a-7b(b).
Rodwin, M A (1993) Medicine, Money and Morals: Physicians’ Conflicts of Interest. New York: Oxford University Press.
Tata Press Ltd v Mahanagar Telephone Nigam Ltd (1995) 5 SCC 139.
TaxGuru (2026) ‘Supreme Court directs regulatory review of UCPMP to safeguard patients’. Available at: https://taxguru.in/?p=1087855.
Trilegal (2024) ‘The Uniform Code for Pharmaceutical Marketing Practices 2024: a potential minefield for pharmaceutical companies’. Trilegal Insights, Issue 12. Available at: https://trilegal.com/magazine/uniform-code-for-pharmaceutical-marketing-practices-2024-potential-minefield-for-pharmaceutical-companies-insights-issue-12.html.
Union of India v Cynamide India Ltd (1987) 2 SCC 720.
Verdictum (2026) ‘Breaking: Supreme Court directs Centre to form committee on unethical pharma practices and mandatory marketing code’. Available at: https://www.verdictum.in/supreme-court/freebies-to-doctor-directs-centre-form-committee-pharma-practices-marketing-code-1623578.
Wazana, A (2000) ‘Physicians and the pharmaceutical industry: is a gift ever just a gift?’ JAMA 283(3): 373–380.
Downloads
Veröffentlicht
Erklärung zur Datenverfügbarkeit
Data used in this research paper is available on public domain but the article curated is published for the first time for public reference.
Ausgabe
Rubrik
URN
Lizenz
Copyright (c) 2026 Oxford Law Review
Dieses Werk steht unter der Lizenz Creative Commons Namensnennung 4.0 International.
Content published by Oxford Law Review is made available subject to the copyright and licensing terms applicable to the individual article.
Unless otherwise stated on the article page, the following terms apply:
1. Copyright
Copyright in published articles remains subject to the rights and terms specified for the respective publication. Authors and users should respect all applicable copyright and intellectual property laws.
2. Use of Published Material
Published articles may be accessed, read, cited and referenced for legitimate scholarly, educational and research purposes, subject to applicable copyright and licensing restrictions.
3. Reproduction
Reproduction, redistribution, adaptation or commercial use of published material is permitted only where expressly authorised by the applicable licence or by the relevant copyright holder.
4. Citation and Attribution
Any permitted use of material published by Oxford Law Review must provide appropriate bibliographic attribution, including the author, article title, Journal name and publication details, and a persistent link to the original article where available.
5. Third-Party Material
Material belonging to third parties, including photographs, illustrations, tables, datasets or other copyrighted content, may be subject to separate copyright or licensing conditions. Users are responsible for obtaining any permission required for such use.
6. Author Rights
Authors retain such rights as are provided under the applicable publication and licensing agreement. The specific rights applicable to each article are indicated with the published work where appropriate.
7. Changes to Licensing Terms
Oxford Law Review may update its licensing terms from time to time. The terms applicable to a published article will be those stated with or otherwise governing that article.
For the licensing status of a particular article, please refer to the licence information displayed on its publication page.
Zitationsvorschlag
